Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Medicenna Therapeutics Corp.
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
October 23, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Therapeutics Announces Participation in Upcoming Conferences
October 20, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
October 01, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Announces Results of Annual Meeting of Shareholders
September 25, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
September 05, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
August 01, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
July 31, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
June 26, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
April 30, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
April 28, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Tickers
MDNAF
TSX:MDNA
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.